Addressing the challenges of vaccine formulation

Formulating a drug for parenteral delivery comes with its fair set of challenges. Aside from a high level of sensitivity to external factors like light and heat exposure, these large and complex drugs are prone to degradation when exposed to various chemical species.

Adjuvants. You’ve seen them on our website. You’ve seen them featured in our blog articles. Now we want to show you how Avanti’ & Croda-Denmark can enhance your vaccine adjuvant research!

Keep reading to learn more!

For over 40 years Avanti has provided API (Active Pharmaceutical Ingredient) Technology Development for Pharmaceutical and Biotechnology companies. Our unique reputation for quality in the development of pre-clinical and clinical candidates is well established. Our full range of services include process chemistry, scale-up manufacturing, supply chain management with analytical and regulatory requirements. Avanti’s experienced staff of chemists and lipid analysts are ready to meet your development needs with pre-clinical through phase III and commercial launch.

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

Croda International Plc, the company that uses smart science to create high performance ingredients and technologies that improve lives, is excited to announce the expansion of its Mill Hall high purity excipients facility. This investment confirms Croda’s commitment to building its Life Sciences business and developing innovative pharmaceutical excipients, reinforcing Croda’s Purpose to use Smart science to improve lives™. With this latest Mill Hall expansion, Croda continues their ambitious target to become People Positive by 2030 by contributing to the successful development of 25% of WHO-listed pipeline vaccines.

To find out more, please visit: https://www.croda.com/en-gb/news/2021/08/croda-expands-its-high-purity-pharmaceutical-excipients-manufacturing-capability

The facility will support the company'a goal of being climate, land and people positive by 2030.

Super Refined™ Polysorbates for Biopharma applications.

This document is relevant to the following market areas

Health Care - DermaHealth Care - Pharma
Health Care - Nutra
Health Care - Animal Health

This document is attached to the following products

Super Refined™ Polysorbate 80

The transaction will more than double Croda’s R&D capability in drug delivery.

Pharmaceutical excipients for ophthalmic formulations.

This document is relevant to the following market areas

Health Care - Derma
Health Care - Pharma
Health Care - Nutra
Health Care - Animal Health

Group aiming to achieve a 50% reduction in absolute GHG emissions based on 2006 levels by 2030 and an 80% reduction by 2050.

Super Refined™ pharmaceutical excipients.

Smart Science to Improve Lives. For more than 75 years Croda Denmark has been dedicated to safe and effective adjuvants for use in both human and veterinary vaccines, as well as blood fractioning processes. We offer an experienced passionate team and personal interaction with comprehensive on-site advice and support anywhere in the world.

The use of cannabinoids (CBD) is a growing marketplace dominated by oral and topical formulations. Croda offers Super Refined™ formulation solutions providing benefits such as; improving stability and reducing taste impact. Find out more here: